Tamoxifen-stimulated growth of breast cancer due to p21 loss

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 1, 2008, Pages 288-293

  Abukhdeir, Abde M ^a   Vitolo, Michele I ^c   Argani, Pedram ^a   De Marzo, Angelo M ^a   Karakas, Bedri ^a   Konishi, Hiroyuki ^a   Gustin, John P ^b   Lauring, Josh ^a   Garay, Joseph P ^a   Pendleton, Courtney ^a   Konishi, Yuko ^a   Blair, Brian G ^a   Brenner, Keith ^a   Garrett Mayer, Elizabeth ^d   Carraway, Hetty ^a   Bachman, Kurtis E ^c,e   Ben, Ho Park ^a,b,f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f CRB I ^*  (United States)

Author keywords

Drug resistance; Estrogen receptor; p21 knockout; Selective estrogen receptor modulator

Indexed keywords

PROTEIN P21; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 38349137676     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0710887105     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467.
2. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618-629.
3. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468.
4. Howell A, Dodwell DJ, Anderson H, Redford J (1992) Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611-617.
5. Legault-Poisson S, et al. (1979) Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep 63:1839-1841.
6. Belani CP, Pearl P, Whitley NO, Aisner J (1989) Tamoxifen withdrawal response. Report of a case. Arch Intern Med 149:449-450.
7. Stein W, III, Hortobagyi GN, Blumenschein GR (1983) Response of metastatic breast cancer to tamoxifen withdrawal: Report of a case. J Surg Oncol 22:45-46.
8. Canney PA, Griffiths T, Latief TN, Priestman TJ (1987) Clinical significance of tamoxifen withdrawal response. Lancet 1:36.
9. Michalides R, et al. (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5:597-605.
10. Shou J, et al. (2004) Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935.
11. Osborne CK, et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361.
12. Rayala SK, Molli PR, Kumar R (2006) Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res 66:5985-5988.
13. Planas-Silva MD, Weinberg RA (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059-4069.
14. Cariou S, et al. (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 97:9042-9046.
15. Bachman KE, et al. (2004) p21(WAF1/CIP1) Mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther 3:221-225.
16. Abukhdeir AM, et al. (2006) Physiologic estrogen receptor alpha signaling in nontumorigenic human mammary epithelial cells. Breast Cancer Res Treat 99:23-33.
17. Sjoblom T, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.
18. el-Deiry WS, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
19. Balbin M, et al. (1996) Functional analysis of a p21WAF1,CIP1,SDI1 mutant (Arg94 → Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J Biol Chem 271:15782-15786.
20. Varshochi R, et al. (2005) ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 280:3185-3196.
21. Duan Z, et al. (2005) Gfi1 coordinates epigenetic repression of p21Cip/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1. Mol Cell Biol 25:10338-10351.
22. Lagger G, et al. (2003) The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 23:2669-2679.
23. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019.
24. Roman-Gomez J, et al. (2002) 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99:2291-2296.
25. Bott SR, Arya M, Kirby RS, Williamson M (2005) p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation. Prostate Cancer Prostatic Dis 8:321-326.
26. Yoon DS, et al. (2002) Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 161:391-397.
27. Bachman KE, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775.
28. Liang X, et al. (2006) Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther 5:544-548.
29. Robertson JF (2001) Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem Mol Biol 79:209-212.
30. Karakas B, et al. (2006) Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells. Oncogene 25:5561-5569.
31. Cayrol C, Knibiehler M, Ducommun B (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16:311-320.
32. Trowbridge JM, Rogatsky I, Garabedian MJ (1997) Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci USA 94:10132-10137.
33. Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54:1587-1595.
34. Wolf DM, Jordan VC (1994) Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 31:117-127.
35. Zhou BP, et al. (2001) Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3:245-252.
36. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618.
37. Dosik M, Kaufman R (2004) Raloxifene rebound regression. Cancer Invest 22:718-722.
38. Domagala W, et al. (2001) p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: Relationship to p53, proliferation rate, and survival at 5 years. Virchows Arch 439:132-140.
39. Winters ZE, et al. (2003) Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 5:R242-R249.
40. Xia W, et al. (2004) Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10:3815-3824.
41. ChuI, et al. (2007) p27 Phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128:281-294.
42. Ho SN, et al. (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.